Jin Chen

Dr. Jin Chen

1. Department of Computer Science, University of Kentucky, Lexington, KY 40536, USA
+1
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2012 in Bioinformatics
Verified
Journal Article
Open access
PDF file
BRBruce A Rosa
Bruce A Rosa
JZJi Zhang
Ji Zhang
Ian MajorIan Major
Ian Major
Wensheng QinWensheng Qin
Wensheng Qin
Jin ChenJin Chen
Jin Chen
Motivation: Determining the best sampling rates (which maximize information yield and minimize cost) for time-series high-throughput gene expression experiments is a challenging optimization problem. Although existing approaches provide insight into the design of optimal sampling rates, our ability to utilize existing differential gene expression data to discover optimal timepoints is compelling. Results: We present a new data-integrative model, Optimal Timepoint Selection (OTS), to address the sampling rate problem. Three experiments were run on two different datasets in order to test the performance of OTS, including iterative-online and a top-up sampling approaches. In all of the experiments, OTS outperformed the best existing timepoint selection approaches, suggesting that it can optimize the distribution of a limited number of timepoints, potentially leading to better biological insights about the resulting gene expression patterns. Availability: OTS is available at www.msu.edu/∼jinchen/OTS. Contact:wqin@lakeheadu.ca; jinchen@msu.edu Supplementary information: Supplementary data are available at Bioinformatics online.

27 February 2021 in Genomics, Proteomics & Bioinformatics
Verified
Journal Article
Open access
ZLZhenlan Liang
Zhenlan Liang
MLMin Li
Min Li
RZRuiqing Zheng
Ruiqing Zheng
YTYu Tian
Yu Tian
XYXuhua Yan
Xuhua Yan
JWJianxin Wang
Jianxin Wang
Accurate identification of cell types from single-cell RNA sequencing (scRNA-seq) data plays a critical role in a variety of scRNA-seq analysis studies. This task corresponds to solving an unsupervised clustering problem, in which the similarity measurement between cells affects the result significantly. Although many approaches for cell type identification have been proposed, the accuracy still needs to be improved. In this study, we proposed a novel single-cell clustering framework based on similarity learning, called SSRE. SSRE models the relationships between cells based on subspace assumption, and generates a sparse representation of the cell-to-cell similarity. The sparse representation retains the most similar neighbors for each cell. Besides, three classical pairwise similarities are incorporated with a gene selection and enhancement strategy to further improve the effectiveness of SSRE. Tested on ten real scRNA-seq datasets and five simulated datasets, SSRE achieved the superior performance in most cases compared to several state-of-the-art single-cell clustering methods. In addition, SSRE can be extended to visualization of scRNA-seq data and identification of differentially expressed genes. The matlab and python implementations of SSRE are available at https://github.com/CSUBioGroup/SSRE.

28 March 2025 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
ACAugusto Cama-Olivares
Augusto Cama-Olivares
CBChloe Braun
Chloe Braun
TTTomonori Takeuchi
Tomonori Takeuchi
EOEmma C. O'HAgan
Emma C. O'HAgan
KKKathryn A. Kaiser
Kathryn A. Kaiser
JNJavier A. Neyra
Javier A. Neyra
Key Points: Pooled discrimination metrics were acceptable (area under the receiver operating characteristic curve >0.70) for all AKI risk classification categories in both internal and external validation. Better performance was observed in most recently published studies and those with a low or unclear risk of bias. Significant heterogeneity in patient populations, definitions, clinical predictors, and methods limit implementation in real-world clinical scenarios. Background: Artificial intelligence through machine learning models seems to provide accurate and precise AKI risk classification in some clinical settings, but their performance and implementation in real-world settings has not been established. Methods: PubMed, Excerpta Medica (EMBASE) database, Web of Science, and Scopus were searched until August 2023. Articles reporting on externally validated models for prediction of AKI onset, AKI severity, and post-AKI complications in hospitalized adult and pediatric patients were searched using text words related to AKI, artificial intelligence, and machine learning. Two independent reviewers screened article titles, abstracts, and full texts. Areas under the receiver operating characteristic curves (AUCs) were used to compare model discrimination and pooled using a random-effects model. Results: Of the 4816 articles initially identified and screened, 95 were included, representing 3.8 million admissions. The Kidney Disease Improving Global Outcomes (KDIGO)-AKI criteria were most frequently used to define AKI (72%). We identified 302 models, with the most common being logistic regression (37%), neural networks (10%), random forest (9%), and eXtreme gradient boosting (9%). The most frequently reported predictors of hospitalized incident AKI were age, sex, diabetes, serum creatinine, and hemoglobin. The pooled AUCs for AKI onset were 0.82 (95% confidence interval, 0.80 to 0.84) and 0.78 (95% confidence interval, 0.76 to 0.80) for internal and external validation, respectively. Pooled AUCs across multiple clinical settings, AKI severities, and post-AKI complications ranged from 0.78 to 0.87 for internal validation and 0.73 to 0.84 for external validation. Although data were limited, results in the pediatric population aligned with those observed in adults. Between-study heterogeneity was high for all outcomes (I 2 >90%), and most studies presented high risk of bias (86%) according to the Prediction Model Risk of Bias Assessment Tool. Conclusions: Most externally validated models performed well in predicting AKI onset, AKI severity, and post-AKI complications in hospitalized adult and pediatric populations. However, heterogeneity in clinical settings, study populations, and predictors limits their generalizability and implementation at the bedside.

1 February 2020 in Methods
Verified
Journal Article
Closed access
TWTao Wang
Tao Wang
JPJiajie Peng
Jiajie Peng
QPQidi Peng
Qidi Peng
YWYadong Wang
Yadong Wang
Jin ChenJin Chen
Jin Chen

10 April 2023 in IEEE Journal of Biomedical and Health Informatics
Verified
Journal Article
Closed access
SFSajjad Fouladvand
Sajjad Fouladvand
JTJeffery Talbert
Jeffery Talbert
LDLinda P. Dwoskin
Linda P. Dwoskin
HBHeather Bush
Heather Bush
AMAmy L. Meadows
Amy L. Meadows
Jin ChenJin Chen
Jin Chen
Opioid use disorder (OUD) is a leading cause of death in the United States placing a tremendous burden on patients, their families, and health care systems. Artificial intelligence (AI) can be harnessed with available healthcare data to produce automated OUD prediction tools. In this retrospective study, we developed AI based models for OUD prediction and showed that AI can predict OUD more effectively than existing clinical tools including the unweighted opioid risk tool (ORT). Data include 474,208 patients' data over 10 years; 269,748 were females with an average age of 56.78 years. Cases are prescription opioid users with at least one diagnosis of OUD or at least one prescription for buprenorphine or methadone. Controls are prescription opioid users with no OUD diagnoses or buprenorphine or methadone prescriptions. On 100 randomly selected test sets including 47,396 patients, our proposed transformer-based AI model can predict OUD more efficiently (AUC=0.742 $\pm$ 0.021) compared to logistic regression (AUC=0.651 $\pm$ 0.025), random forest (AUC=0.679 $\pm$ 0.026), xgboost (AUC=0.690 $\pm$ 0.027), long short-term memory model (AUC=0.706 $\pm$ 0.026), transformer (AUC=0.725 $\pm$ 0.024), and unweighted ORT model (AUC=0.559 $\pm$ 0.025). Our results show that embedding AI algorithms into clinical care may assist clinicians in risk stratification and management of patients receiving opioid therapy.

7 August 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
DWDuolin Wang
Duolin Wang
MPMahdi Pourmirzaei
Mahdi Pourmirzaei
UAUsman L Abbas
Usman L Abbas
SZShuai Zeng
Shuai Zeng
NMNegin Manshour
Negin Manshour
DXDong Xu
Dong Xu
Proteins play an essential role in various biological and engineering processes. Large protein language models (PLMs) present excellent potential to reshape protein research by accelerating the determination of protein function and the design of proteins with the desired functions. The prediction and design capacity of PLMs relies on the representation gained from the protein sequences. However, the lack of crucial 3D structure information in most PLMs restricts the prediction capacity of PLMs in various applications, especially those heavily dependent on 3D structures. To address this issue, we introduce S-PLM, a 3D structure-aware PLM that utilizes multi-view contrastive learning to align the sequence and 3D structure of a protein in a coordinated latent space. S-PLM applies Swin-Transformer on AlphaFold-predicted protein structures to embed the structural information and fuses it into sequence-based embedding from ESM2. Additionally, we provide a library of lightweight tuning tools to adapt S-PLM for diverse protein property prediction tasks. Our results demonstrate S-PLM’s superior performance over sequence-only PLMs on all protein clustering and classification tasks, achieving competitiveness comparable to state-of-the-art methods requiring both sequence and structure inputs. S-PLM and its lightweight tuning tools are available at https://github.com/duolinwang/S-PLM/ .